(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.47%.
Immunitybio's revenue in 2025 is $82,555,000.On average, 7 Wall Street analysts forecast IBRX's revenue for 2025 to be $111,419,261,048, with the lowest IBRX revenue forecast at $104,948,039,822, and the highest IBRX revenue forecast at $119,456,576,909. On average, 7 Wall Street analysts forecast IBRX's revenue for 2026 to be $209,827,132,082, with the lowest IBRX revenue forecast at $150,384,483,530, and the highest IBRX revenue forecast at $254,160,414,789.
In 2027, IBRX is forecast to generate $552,792,007,410 in revenue, with the lowest revenue forecast at $267,093,007,589 and the highest revenue forecast at $808,331,373,450.